Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort by Roen, A et al.
1 
 
Abacavir Usage Patterns and Hypersensitivity Reactions (HSR) in the EuroSIDA cohort 
Ashley Roen1, Kamilla Laut2, Annegret Pelchen-Matthews1, Elena Borodulina3, Luis Caldeira4, Amanda Clarke5, 
Bonaventura Clotet6, Antonella d'Arminio Monforte7, Gerd Fätkenheuer8, Jose M. Gatell Artigas9, Igor Karpov10, 
Anastasiia Kuznetsova11, Galina Kyselyova12, Iwona Mozer-Lisewska13, Fiona Mulcahy14, Leigh Ragone15, Alexandra 
Scherrer16, Vilma Uzdaviniene17, Linos Vandekerckhove18, Vani Vannappagari15, Lars Ostergaard19, Amanda Mocroft1 
on behalf of the EuroSIDA study*  
1 University College London, London, UK 
2 University of Copenhagen, Copenhagen, Denmark 
3 Samara State Medical University, Samara, Russia 
4 Hospital Santa Maria, Lisbon, Portugal 
5 Royal Sussex County Hospital, Brighton, UK 
6 Hospital Universitari Germans Trias i Pujol, Barcelona, Spain 
7 Ospedale San Paulo, Milan, Italy 
8 University Hospital Cologne, Cologne, Germany 
9 Hospital Clinic, Barcelona, Spain 
10 Belarus State Medical University, Minsk, Belarus 
11 Kharkov State Medical University, Khrakov, Ukraine 
12 Crimean Republican AIDS centre, Simferopol, Ukraine 
13 Poznan University of Medical Sciences, Poznań, Poland 
14 St. James' Hospital, Dublin, Ireland 
15 ViiV Healthcare, RTP, North Carolina, USA 
16 University Hospital Zürich, Zürich, Switzerland 
17 Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania 
18 University Ziekenhuis Gent, Gent, Belgium 
19 Aarhus universitetshospital, Skejby, Denmark 
*Study group listed in appendix 
Correspondence to: Ashley Roen. University College London, London UK. a.roen@ucl.ac.uk   
Funding: EuroSIDA was supported by the European Union’s Seventh Framework Programme for research, 
technological development and demonstration under EuroCoord grant agreement n˚ 260694. Current support 
includes unrestricted grants by Bristol-Myers Squibb, Gilead, GlaxoSmithKline LLC, Janssen R&D, Merck and Co. Inc., 
Pfizer Inc. The participation of centres from Switzerland was supported by The Swiss National Science Foundation 
(Grant 108787). The study is also supported by a grant [grant number DNRF126] from the Danish National Research 
Foundation. This analysis was funded by ViiV Healthcare. 
Word Count: abstract (222), main text (2,243) 





Objective: 5-8% of HIV-positive individuals initiating abacavir (ABC) experience potentially fatal hypersensitivity 
reactions (HSR).  
Methods: We calculated the proportion of EuroSIDA individuals receiving ABC-based cART among those receiving 
cART after 1/1/2009. Poisson regression was used to identify demographic, and current clinical and laboratory 
factors associated with ABC utilization and discontinuation. 
Results: Between 2009-2016, of 10,076 individuals receiving cART, 3,472 (34%) had ever received ABC-based cART.  
Temporal trends of ABC utilization were also heterogeneous, 28% in 2009, dropping to 26% in 2010 and increasing to 
31% in 2016, and varied across region and time. Poisson models showed lower ABC utilization in older individuals, 
those with higher CD4 cell-counts, higher cART lines, and prior AIDS. Higher ABC utilization was associated with 
higher HIV-RNA, poor renal function, and was more common in Central-East and Eastern Europe and lowest during 
2014. During 779 PYFU in 2,139 individuals starting ABC after 1/1/2009, 113 discontinued ABC within 6 weeks of 
initiation for any reason (IR =14.5 (12.1, 17.5) per 100-person-year follow-up), 13 due to reported HSR (IR =0.3 (0.1, 
1.0)) and 35 due to reported HSR/any toxicity (IR = 4.5 (3.2, 6.3)). There were no factors significantly associated with 
ABC discontinuation due to reported HSR/any toxicity. 
Conclusion: ABC remains commonly used across Europe and the incidence of discontinuation due to reported HSR 






In the absence of genetic screening, hypersensitivity reaction (HSR) presents in approximately 5-8% of persons living 
with HIV (PLHIV) initiating abacavir 1,2(ABC).  HSR can vary in severity and clinical manifestation indicative of 
multiorgan involvement and includes fever, skin rash, constitutional,  gastrointestinal tract  and respiratory 
symptoms 1-5. In rare cases, HSR is fatal6,7. Risk of ABC HSR is high for patients who test positive for the HLA-B*5701 
allele1,8,9; however, ABC HSRs have been reported at a lower frequency in patients who do not carry this allele and 
therefore risk for HSR can be reduced by HLA B*5701 screening.1,3 ABC should never be initiated in patients with a 
positive HLA-B*5701 status, and ABC re-challenge among those previously experiencing HSR is contraindicated, as 
acute onset of potentially fatal symptoms have been reported2,10-12.  
ABC remains  a commonly used drug throughout Europe and is recommended as a part of first line therapy by 
national and international guidelines13,14; it is therefore important to continually examine safety of ABC over time. A 
previous 2008 report using data from EuroSIDA, a longitudinal cohort collaboration across 35 countries across 
Europe plus Israel and Argentina15, showed the HSR incidence within 3 months of starting ABC of 22.1 (18.7, 25.4) 
per 100 person-years follow-up with a decreasing trend for ABC discontinuation due to HSR over time16. HSR due to 
ABC typically presents within 6 weeks of therapy initiation4,17, and presentation of HSR later than 8 weeks after ABC 
initiation is almost always due to other causes18.   
The objectives of this study were twofold. First, to describe the proportion of individuals across Europe on 
combination antiretroviral therapy (cART) receiving an ABC based regimen from 1/1/2009 to 1/4/2016 and the 
factors associated with ABC initiation. Second, we sought to describe the cumulative frequency, incidence and 
factors associated with ABC discontinuation due to reported HSR or due to reported HSR/any toxicity among those 





EuroSIDA is a longitudinal observational cohort study that was initiated in 1994, and has been previously described15. 
The data collected includes start and stop dates for each antiretroviral drug used, reasons for discontinuing an 
antiretroviral drug and clinical events.  Further details on data collected can be found at www.cphiv.dk. 
Individuals from the EuroSIDA cohort over the age of 16 at enrolment receiving cART (at least 3 drugs from any class, 
excluding ritonavir) after 1/1/2009 were included in the ABC utilisation over time analysis.  All persons starting ABC 
based cART after 1/1/2009 were eligible for inclusion for analyses of reported HSR related discontinuation. 
Statistical Methods 
Among those receiving cART and under active follow-up, the proportion of individuals who received ABC at the 
midpoint of each calendar year (July 1st) from 1/1/2009 onwards and by geographical region was summarised using 
descriptive statistics. Active follow-up was defined as having a first visit date before and last visit date after the 
midpoint of the year.  
Factors associated with ABC utilization were investigated using Poisson regression with generalised estimating 
equations (GEE) to control for the inclusion of repeated exposuresand events. Baseline was defined as 1/1/2009 or 
enrolment into EuroSIDA, whichever occurred later. Individuals off ABC contributed follow-up (FU) until ABC 
initiation, the last EuroSIDA visit date or death, whichever occurred first. If an individual stopped ABC they were 
allowed to re-enter the analysis, and once again considered eligible for starting ABC. Factors that were significantly 
associated with ABC initiation (p<0.1) in univariate analyses were included in multivariable models. Factors 
investigated were gender, age, ethnicity, HIV transmission risk group, region of care, calendar year, CD4 cell count, 
nadir CD4 cell count, HIV-RNA, line of cART regimen, Hepatitis B and C status, previous AIDS diagnosis, Framingham 
10 year elevated cardiovascular disease (CVD) risk19, chronic kidney disease (CKD), and  Data on Adverse 
Drugs(D.A.D) CKD risk20,21. Line of cART regimen captured the extent of previous antiretroviral treatment and 
treatment failure and was defined as a change in at least 2 ARV drugs accompanied by an HIV-RNA > 500 copies/ml, 
or more than 6 months off treatment before starting a new therapy.   CKD was defined as 2 consecutive eGFRs < 60 
more than three months apart using the CKD EPI formula22.  
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For the second objective, analysing reported HSR related discontinuation, individuals were included if they initiated 
ABC as part of cART after 1/1/2009. Individuals with prior ABC exposure were included, and individuals who started 
ABC more than once after 1/1/2009 could contribute multiple exposure periods. Baseline was defined as the start of 
an ABC-containing regimen, 1/1/2009 or recruitment to EuroSIDA, whichever occurred later.  This was an on-
treatment analysis where individuals contributed follow-up until 6 weeks after ABC initiation, ABC discontinuation 
due to any cause, death or their last visit date, whichever occurred first.  The primary outcome was discontinuation 
due to reported HSR.  We also analyzed a composite outcome of discontinuation due to reported HSR or any toxicity, 
as well as investigating all reasons for discontinuation to account for underreporting and potentially undiagnosed 
HSR cases. 
Factors associated with reported HSR or any toxicity related discontinuation were identified in a multivariable 
Poisson Regression Model using GEE to adjust for repeated events; those that were significant (p<0.1) in univariable 






Among 10,076 individuals in EuroSIDA receiving cART between 1/1 2009 and 4/1 2016, 3472 (34%; 95% CI (34-35)) 
had ever received ABC during follow-up (Table 1).  74% were male and 27% were female with HIV risk-group of sex 
between men (MSM) (40%), injection drug users (IDU) (22%) sex between men and women (MSW) (31%) or 
other/unknown (7%). The highest proportion received care in Southern Europe (28%) followed by Western Europe 
(25%), Northern Europe (22%), Central-East Europe (14%), and Eastern Europe (12%). Median baseline age was 45 
years (IQR: 37, 52). In general, demographic characteristics among those exposed to ABC were similar to those not 
exposed, apart from baseline age, with those receiving ABC slightly older than those not receiving ABC.  Baseline 
HIV-RNA values among those initiating ABC were slightly higher compared to those not exposed to ABC, and there 
was also a higher prevalence of AIDS among those initiating ABC.  
ABC utilization and factors associated with starting ABC 
ABC utilization significantly varied over time, starting at 28% in 2009, dropping to 26% in 2010 and increasing to 31% 
in 2016. (p-heterogeneity from univariate analysis = <0.001) Figure 1. There was a significant interaction with region 
and time where ABC utilization in Northern Europe decreased, Southern and Eastern Europe increased and Western 
and Central-East Europe remained relatively consistent with time (p-interaction < 0.001).   
Using multivariable Poisson regression, factors associated with lower rates of ABC utilization were older age (IRR = 
0.73 (0.59, 0.90) for highest age quintile, >58 compared to the lowest, 18-41), higher CD4 cell counts (IRR = 0.68 
(0.56, 0.82) for CD4 > 500 compared to CD4 < 200 cells/mm3), and those exposed to more cART treatment regimens 
(IRR = 0.55 (0.46, 0.66) for 4th+ line compared to first line regimens), and having a previous AIDS diagnosis (IRR = 0.9 
(0.8, 1.0) compared to those without a previous AIDS diagnosis). Higher ABC utilization rates were associated with 
higher HIV-RNA copies/ml (IRR =1.92 (1.47, 2.51) for HIV-RNA > 100k compared to <500 copies/ml), CKD (IRR = 2.62 
(2.06, 3.34) compared to those without CKD), and higher DAD CKD risk scores (IRR = 1.18 (1.01, 1.38) for those at 
high risk compared to low risk).  There was heterogeneity in ABC utilization among region; those in Central-East and 
Eastern Europe were more likely to initiate ABC compared to Southern Europe; IRR = 1.58 (1.35, 1.84) and 1.71 (1.42, 
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2.05).  Persons under follow-up in 2014 were less likely to start ABC compared to those under follow-up in 2009 (IRR 
= 0.69 (0.57, 0.85)) Figure 2.   
Discontinuation of ABC 
Among 2,139 individuals initiating ABC after 1/1/2009, contributing 778 person years of follow-up, 113 (5.3%) 
individuals discontinued ABC within 6 weeks of ABC initiation, an incidence rate of 14.51 (12.07, 17.45) per 100 
person-years follow-up. The most common single reason for discontinuation within the first 6 weeks was unknown, 
followed by the patient’s wish/decision, then other causes.  13 individuals (0.6%) discontinued due to reported HSR 
(IR =1.67 (0.97, 2.87)) and 35 (4.6%) discontinued due to reported HSR or any toxicity, IRR = 4.49 (3.23, 6.26) per 100 
person-years follow-up, Table 2.  
As only 13 persons discontinued due to reported HSR, we could not formally investigate factors associated with 
reported HSR related discontinuation.  Expanding the endpoint to discontinuation due to reported HSR or any 
toxicity did not identify any factors associated with discontinuation.   The strongest factor associated with 
discontinuation for reported HSR/any toxicity was nadir CD4 cell count, where those with a nadir CD4 cell count of 
350-500 cells/mm3 were at the highest risk of discontinuing due to reported HSR/any toxicity (IRR = 1.60 (0.59, 4.37) 
compared to those with  CD4 <200 cells/mm3, p-heterogeneity = 0.078).  This analysis had limited power as there 
were few events (n=35). 
Seven individuals died within 6 weeks of initiating ABC, all with advanced HIV disease and other comorbidities. HSR 





Despite the risk of HSR, ABC remains a commonly used ARV drug across Europe in EuroSIDA. Among individuals 
initiating ABC based cART after 2009, there were very few discontinuations within 6 weeks of ABC initiation, and 
discontinuation rates due to reported hypersensitivity reactions were 0.3 (0.1, 1.0) per 100 person-years follow-up.  
There were 7 deaths within 6 weeks of starting ABC, but these were likely due to causes unrelated to ABC HSR 
reactions. 
ABC utilization was lower among individuals exposed to more treatment regimens and had previous ABC exposure. 
Because there is evidence to suggest ABC re-challenge should be avoided5,12,23, it is possible this result is due to 
lower ABC prescription rates among those already exposed to ABC. Unexpectedly, higher ABC utilization was 
associated with CKD and higher DAD CKD risk scores, though this could be attributed to confounding by indication.  
Use of tenofovir has been linked to kidney disease24 and individuals on tenofovir with decreasing renal function are 
likely to discontinue tenofovir25 and be switched to ABC26, a drug with no reported adverse effect on renal function.   
Changes over time and within regions in use of abacavir likely reflects marketing and availability of abacavirt.  
Overall, the rate of discontinuation of ABC in the first 6 weeks after starting ABC was low, which is similar to Phase II 
clinical trials27,28, but slightly lower than previous EuroSIDA findings16, although the previous EuroSIDA report had a 
much larger window to observe reported HSR cases (3 months vs. 6 weeks in our study).  The rate of stopping due to 
reported HSR or the composite endpoint of reported HSR or any toxicity was also low, which could indicate the 
effectiveness of screening for HLA B*5701, better patient care and a greater understanding of HSR among treating 
physicians. Screening uptake for the HLA B*5701 allele has likely avoided many HSR reactions in recent years. 
EuroSIDA does not collect genetic screening information, thus it is unknown which individuals were tested for HLA 
B*5701, or whether the frequency of testing varied between regions and/or over calendar time.   
It is possible that we found low rates of discontinuation due to using a 6-week window from ABC initiation, but it is 
well established that this is when HSR is most likely to occur18.  Even so, compared to early cART, where 
discontinuation rates at 3 months have reported between 10-15%29,30, discontinuation due to ABC was low, 
indicating the effectiveness of screening for HLA B*5701, improved patient management, improved ARV regimens, 
reduction in toxicities, and improved adherence31. We found no factors significantly associated with ABC 
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discontinuation due to reported HSR/any toxicity, though this might partly be due to low power as few patients 
discontinued. 
Along with lack of data on HLA B*5701 screening, there are other limitations to our study. Most notably, the 
symptoms of HSR can be difficult to distinguish from other adverse events in the population, possibly leading to over 
or underreporting of discontinuation due to reported HSR. EuroSIDA also only collects one reason for discontinuing a 
drug, so if HSR and another simultaneous reason for discontinuation occurred, HSR may have not been reported as 
the reason for discontinuation in our data.  We have investigated underreporting by using a composite outcome of 
reported HSR or any toxicity, with consistent results.  Finally, the validity of our models depends on the assumption 
that we appropriately adjusted for confounding; it is however possible that our models have residual confounding by 
indication.  Nonetheless, EuroSIDA is in a unique position to compare and describe treatment patterns due to the 
standardised nature of the data collection and the inclusion of countries for which there are no national cohorts or 
surveillance structures.   
This study also has several strengths including the use of a large dataset from a heterogeneous population, and 
including data from Eastern Europe. In addition, EuroSIDA covers the period 1994-2016 with consistent records of all 
ARV use and reasons for stopping, allowing for comparisons of temporal trends of ABC utilization and subsequent 
HSR.  There has also been consistency in the way ARVs were collected and the subsequent reasons for stopping over 
our study duration. 
In summary, ABC remains a commonly used drug throughout Europe, and the incidence of reported hypersensitivity 
reaction among those on ABC is low, likely attributable to screening for HLA B*5701, improved patient care and a 




Table 1: Baseline characteristics of all participants, split by ABC use (total vs. no ABC vs. ever ABC) in the EuroSIDA 
cohort from 1/1/2009 to 4/1/2016 
   Total    No ABC     ABC    
  No. %   No. %   No. % p-value 
Gender          
  Female 7408 74  4926 75  2482 72 0.001 
  Male 2668 27  1678 25  990 29  
Region of care in Europe        
  South  2819 28  1962 30  857 25 <0.001 
  West  2478 25  1672 25  806 23  
  North  2187 22  1348 20  839 24  
  Central-East  1430 14  897 14  533 15  
  East  1162 12  725 11  437 13  
Ethnicity          
  White 8,827 88  5,773 87  3,054 88 0.291 
  Black 563 6  361 6  202 6  
  Asian 163 2  108 2  55 2  
  OTH/NK 523 5  362 6  161 5  
HIV-Risk group          
  MSM 4,054 40  2,701 41  1,353 39 0.171 
  IDU 2,198 22  1,438 22  760 22  
  MSW 3,138 31  2,012 31  1,126 32  
  OTH/NK 686 7  453 7  233 7  
Calendar year*ł 2009 (2009, 2011)  2009 (2009, 2011)  2011 (2009, 2010) 0.001 
Baseline Age ł 45 (37, 52)  45 (37, 51)  51 (38, 52) 0.001 
Baseline HIV-RNA ł 49 (39, 74)  49 (39, 71)  71 (33, 90) <0.001 
Baseline CD4 cell 
count ł 490 (337, 688)  488 (340, 679)  679 (333, 709) 0.385 
CKD          
  No 7,354 84  5,597 85  1,757 51 <0.001 
  Yes 172 2  106 2  66 2  
  missing 1,232 14  901 14  1,649 47  
AIDS          
  No 6,848 68  4,559 69  2,289 66 0.001 
  Yes 3,228 32  2,045 31  1,183 34  
cART line          
   1st 5,859 58  3,815 58  2,044 59 <0.001 
  2nd 2,043 20  1,307 20  736 21  
  3rd 964 10  611 9  353 10  
  4th+ 1,210 12   871 13   339 10   
Baseline is defined as entry to the study which is 1/1/2009 or enrolment into EuroSIDA, whichever occurred latest.  
% are column percentages 
* calendar year for the first ABC utilization date in the follow-up period 
ł values are median (IQR) 
Region of care in Europe includes South: Argentina, Greece, Israel, Italy, Portugal, Spain; West: Austria, Belgium, France, Germany, 
Luxembourg, Switzerland, North: Denmark, Finland, Iceland, Ireland, Netherlands, Norway, Sweden, United Kingdom; Central-East: Bosnia and 
Herzegovina, Bulgaria, Croatia, Czech Republic, Hungary, Poland, Romania, Serbia; Slovakia, Slovenia East: Belarus, Estonia, Georgia, Latvia, 
Lithuania, Russian Federation, Ukraine. 




Figure 1: Percent prescribed abacavir at the midpoint of each year overall by year and region in the EuroSIDA cohort 
from 2009 -2016 
 
  
Region of care in Europe includes South: Argentina, Greece, Israel, Italy, Portugal, Spain; West: Austria, Belgium, France, Germany, 
Luxembourg, Switzerland, North: Denmark, Finland, Iceland, Ireland, Netherlands, Norway, Sweden, United Kingdom; Central-East: Bosnia and 
Herzegovina, Bulgaria, Croatia, Czech Republic, Hungary, Poland, Romania, Serbia; Slovakia, Slovenia East: Belarus, Estonia, Georgia, Latvia, 































Figure 2: Multivariable incidence rate ratios for ABC utilization in the EuroSIDA cohort from 1/1/2009 to 4/1/2016 
  
All clinical and laboratory variables are time updated; CKD = Chronic kidney Disease defined as 2 consecutive eGFRs < 60 more than 3 months 
apart using the CKD EPI formula; Other variables in the model include Gender, Framingham CVD 10 year elevated risk, HCV, and HBV status, 
DAD CKD risk score and previous AIDS diagnosis.  
Region of care in Europe includes South: Argentina, Greece, Israel, Italy, Portugal, Spain; West: Austria, Belgium, France, Germany, 
Luxembourg, Switzerland, North: Denmark, Finland, Iceland, Ireland, Netherlands, Norway, Sweden, United Kingdom; Central-East: Bosnia and 
Herzegovina, Bulgaria, Croatia, Czech Republic, Hungary, Poland, Romania, Serbia; Slovakia, Slovenia East: Belarus, Estonia, Georgia, Latvia, 
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Table 2. Reasons and incidence rates for ABC discontinuation by reason for stopping treatment in the EuroSIDA 
cohort from 1/1/2009 to 4/1/2016. Individuals were censored at 6 weeks after ABC initiation, ABC discontinuation or 
death, whichever came first.  
Reason for stopping treatment as reported to EuroSIDA Failures Rate 95% CI 
Any Reason 113 14.51 (12.07, 17.45) 
HSR or any toxicity 35 4.49 (3.23, 6.26) 
Any toxicity 22 2.82 (1.86, 4.29) 
Unknown 21 2.70 (1.76, 4.14) 
Patient's wish/decision 20 2.57 (1.66, 3.98) 
Other causes 17 2.18 (1.36, 3.51) 
Physician's decision 16 2.05 (1.26, 3.35) 
Toxicity  - GI tract 16 2.05 (1.26, 3.35) 
HSR 13 1.67 (0.97, 2.87) 
Toxicity – Liver 2 0.26 (0.06, 1.03) 
Toxicity, predominantly CNS 2 0.26 (0.06, 1.03) 
Toxicity, predominantly kidneys 2 0.26 (0.06, 1.03) 
Treatment Failure 1 0.13 (0.02, 0.91) 
Concern of cardiovascular disease, including dyslipidaemia 1 0.13 (0.02, 0.91) 
Other Toxicity 1 0.13 (0.02, 0.91) 
Non-compliance 1 0.13 (0.02, 0.91) 
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